Table 3.

Effects of n-3 fatty acids on serum concentrations of IL-6, hsCRP and NT-proBNP

Biomarker	n-3 fatty acids				Placebo				Difference in change from baselinea
	N	Geometric mean (SD)	Change from baseline (ratio), geometric mean (SD)		N	Geometric mean (SD)	Change from baseline (ratio), geometric mean (SD)		Ratio of change from baseline, active to placebo (95% CI)	p value
IL-6 (pg/ml)
Baseline	655	1.18 (2.78)	1.00 (Ref.)		647	1.24 (3.27)	1.00 (Ref.)		1.00 (Ref.)
Year 2	497	1.19 (3.21)	1.09 (3.76)		491	1.34 (4.23)	1.14 (5.1)		0.95 (0.78, 1.16)
Year 5	472	1.26 (3.65)	1.1 (4.33)		461	1.16 (3.11)	1.02 (4.6)		1.08 (0.88, 1.31)	0.46
hsCRP (mg/l)
Baseline	656	2.03 (3.16)	1.00 (Ref.)		650	1.85 (3.10)	1.00 (Ref.)		1.00 (Ref.)
Year 2	498	1.88 (3.21)	0.97 (2.69)		490	1.85 (3.09)	1.04 (2.72)		0.94 (0.83, 1.06)
Year 5	462	1.72 (3.36)	0.9 (2.82)		454	1.80 (3.33)	1.05 (2.89)		0.86 (0.76, 0.98)b	0.067
NT-proBNP (ng/l)
Baseline	656	276.9 (3.5)	1.00 (Ref.)		650	247.2 (3.8)	1.00 (Ref.)		1.00 (Ref.)
Year 2	498	369.6 (3.7)	1.27 (2.76)		491	264.3 (3.7)	1.14 (2.73)		1.11 (0.97, 1.25)
Year 5	472	424.9 (3.9)	1.56 (3.07)		462	359.3 (3.8)	1.54 (3.24)		1.01 (0.88, 1.16)	0.24

^aFrom a linear mixed model that includes adjustment for age, sex, baseline eGFR and baseline urine albumin to creatinine ratio, and accounts for missing data using multiple imputation

^bp value=0.02 for ratio of change from baseline at year 5

p value comes from a global test of the ratio of change from baseline at years 2 and 5 Ref., reference group